Sanofi-Aventis weight-loss drug may trigger suicidal behavior: FDA

Share this article:

The FDA said Monday that Sanofi-Aventis’ weight-loss drug Acomplia (rimonabant) may trigger suicidal behavior and other psychological side effects in some patients.

 

The agency posted its a review of the drug online ahead of a Wednesday meeting which outside experts are expected to vote on whether rimonabant should be approved.

 

Although the FDA does not have to follow the advice of its outside expert panels, it often does.

 

The FDA is scheduled to issue a final decision on the drug July 27.

Clinical studies from the drug’s maker show that patients taking rimonabant displayed significant weight loss after two years. However agency staffers raised concerns about an increased rated of psychiatric adverse events among patients taking rimonabant including depression, anxiety and insomnia.

 

The FDA noted a possible link between rimonabant and suicidal behavior.

In studies of the drug, Sanofi-Aventis reported one patient committing suicide and eight patients with suicidal thoughts. Among patients taking a placebo, Sanofi-Avnentis reported two suicide attempts and five cases of suicidal thoughts.

 

Shares of Sanofi-Aventis fell 19 cents to $45.31 in early trading on Monday. 

Rimonabant is considered a potential blockbuster despite hitting multiple regulatory

bumps that have left Wall Street analysts questioning the drug’s future.

 

“With the initial demand for Acomplia (rimonabant) likely to be massive, the known neuropsychiatric side effects may make it difficult for the FDA to see a positive risk-benefit ratio,” wrote Citigroup analyst Kevin Wilson.

 

According to Wilson, the FDA review of the drug will likely focus more on safety than effectiveness and drive Sanofi-Aventis’ stock price down.

 

Sanofi-Aventis originally touted rimonabant as an anti-obesity and anti-smoking treatment because it stops cravings associated with addictive behavior.

 

Last February, the FDA rejected Sanofi-Aventis’ application for the anti-smoking use and said it needed more information before approving the drug to fight obesity.

 

If rimonabant is approved in the US, Sanofi-Aventis said it would market the drug under the drug name Zimulti, because FDA reviewers felt its previously proposed brand name of Acomplia could be misleading to consumers.

 

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...